Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma	B-cell neoplasm, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 1	2026-09-10		NCT05272384

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope Comprehensive Cancer Center	Duarte	United States	263
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	United States	188
NYU Langone Hospital - Long Island	Mineola	United States	107
UC Comprehensive Cancer Center at Silver Cross	New Lenox	United States	136
University of Alabama at Birmingham Cancer Center	Birmingham	United States	186
University of California Davis Comprehensive Cancer Center	Sacramento	United States	299
University of Chicago Comprehensive Cancer Center	Chicago	United States	273
University of Chicago Medicine-Orland Park	Orland Park	United States	124
Yale University	New Haven	United States	352